CN1686423A - Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method - Google Patents

Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method Download PDF

Info

Publication number
CN1686423A
CN1686423A CN 200510067854 CN200510067854A CN1686423A CN 1686423 A CN1686423 A CN 1686423A CN 200510067854 CN200510067854 CN 200510067854 CN 200510067854 A CN200510067854 A CN 200510067854A CN 1686423 A CN1686423 A CN 1686423A
Authority
CN
China
Prior art keywords
pharmaceutical composition
radix bupleuri
group
ethanol
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 200510067854
Other languages
Chinese (zh)
Other versions
CN100512796C (en
Inventor
邝继鲜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yangzi Pharmaceutical Group Jiangsu Longfeng Traditional Chinese Medicine Co Ltd
Yangtze River Pharmaceutical Group Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB2005100678542A priority Critical patent/CN100512796C/en
Publication of CN1686423A publication Critical patent/CN1686423A/en
Application granted granted Critical
Publication of CN100512796C publication Critical patent/CN100512796C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

An orally taken Chinese medicine for treating influenze and upper respiratory tract infection features that it contains proportionally scutelloside, the extract of bupleurum root, artificial bezoar and medicinal carrier. Its preparing process is also disclosed.

Description

A kind of pharmaceutical composition that contains baicalin and Radix Bupleuri and preparation method thereof
Technical field
The invention belongs to field of pharmaceutical preparations, more particularly, relate to and a kind ofly be used for the treatment of influenza or go up the heating that sense causes, the pharmaceutical preparation of symptoms such as pain.
Background technology
The heating that influenza or last sense cause, pain etc. are many diseases that caused by pathogenic bacteria poison or bacterial infection.This disease is human commonly encountered diseases, frequently-occurring disease, how because resistance of human body reduces, is subjected to due to pathogenic bacteria poison or the bacterial infection,
At present the medicine of this class disease of treatment is many, but it is few to form the influenza that preparation for treating virus causes with Chinese medicine.。
The heating that current treatment influenza or last sense cause, there are the following problems in the pharmaceutical preparation of symptoms such as pain:
1. the chemicals side effect is bigger, draws symptoms such as drowsiness, tired, weak, dizzy and xerostomia after some common drug patient takes.That have even cause serious adverse effects such as leukopenia.
2. influenza or go up that sense is many to be caused by viral infection, but the medicine of the viral infection of Chinese medicine preparation treatment at present is few, often is symptomatic treatment.
3. the virus of Chinese medicine preparation treatment at present causes influenza or goes up the heating that sense causes, the pain effect is slower.Baikal skullcap root has heat clearing and damp drying, the effect of eliminating fire and detoxication, bupleurum Chinese also has the analgesic effect of delivering, both are share preparation be used for the treatment of the anemopyretic cold medicine, existing in the prior art report, a kind of Chinese medicine oral liquid by Radix Scutellariae and Radix Bupleuri preparation is for example disclosed among the CN1049600C, but this oral liquid is by almost the Radix Scutellariae and the Radix Bupleuri of equivalent obtain fully through the decocting boiling, macromolecular compound such as contained water soluble ingredient tannin is more in the gained oral liquid, form precipitation easily, cause the oral liquid instability, be difficult to long preservation, therefore, needs add antiseptic such as sodium benzoate; And because this oral liquid boils by decocting and obtains, and active constituent content is low, reach required drug effect, patient need take in a large number, has increased toxic and side effects, and is difficult to be accepted by patient.
Directly carry out combined preparation medicine, particularly solid preparation, yet there are no report with baicalin and Radix Bupleuri extract.The artificial Calculus Bovis is mainly contained cholic acid, bilirubin, has heat-clearing and toxic substances removing, the effect of enhancing immunity, and the medicine with baicalin, Radix Bupleuri and artificial Calculus Bovis's combined preparation does not appear in the newspapers yet.
Summary of the invention
The purpose of this invention is to provide a kind of virus that is used for the treatment of causes influenza or goes up the heating that sense causes; the Chinese medicine preparation of pain; this pharmaceutical composition is an effective ingredient with radix scutellariae extract or baicalin, Radix Bupleuri; randomly also contain the artificial Calculus Bovis as effective ingredient; wherein; baicalin is 1~4 part by weight, and Radix Bupleuri (raw material) is 5~50 parts,, the artificial Calculus Bovis is 0~5 part.Promptly; pharmaceutical composition provided by the invention can be that active component prepares by baicalin and Radix Bupleuri extract, in order to bring into play drug effect better, also can add the artificial Calculus Bovis in said medicine; prepare by baicalin the pharmaceutical composition that Radix Bupleuri extract and artificial Calculus Bovis form.
Preferably, contain 1~2 part of baicalin by weight in the pharmaceutical composition provided by the invention, by Radix Bupleuri extract and 1~2 part of artificial Calculus Bovis of 10~20 parts of Radix Bupleuri preparations.
More preferably, in a specific embodiments of the present invention, aforementioned pharmaceutical compositions contains 9 weight portion baicalins, 100 weight portion Radix Bupleuri (raw material) and 10 weight portion artificial Calculus Boviss.
Radix Bupleuri of the present invention can be by the preparation of following method: with 50%~80% ethanol lixiviate one or many, relative density was 1.15~1,25 when filtrate was concentrated into 50 ℃ of heat surveys with Radix Bupleuri.For example Radix Bupleuri (being preferably the Radix Bupleuri decoction pieces that cooks) is pulverized and is added 3~6 times of amounts and (please illustrate by weight or by volume?) 50%~80% ethanol lixiviate of (being preferably 5 times of amounts), wherein ethanol is preferably 60% ethanol water; Randomly 2) filter, lixiviate is once extremely repeatedly again to add 3~6 times of amounts (being preferably 4 times of amounts) 50%~80% ethanol (being preferably 60% ethanol water) in medicinal residues; 3) merge extractive liquid,, relative density is 1.15~1.25 when being evaporated to 50 ℃ of heat surveys, preferably being concentrated into relative density is 1.20~1.25, obtains Radix Bupleuri extractum.
Pharmaceutical composition of the present invention can be prepared to various dosage forms, can be oral formulations, also can be non-oral formulation.Wherein oral formulations can be an oral solid formulation, also can be oral liquid, and oral solid formulation can be capsule, tablet, granule, dispersible tablet, effervescent tablet, chewable tablet, soft capsule or pill; Oral liquid can be oral liquid, mixture or syrup etc.For example in an embodiment preferred of the present invention, pharmaceutical composition of the present invention is a capsule, and in another preferred such scheme, pharmaceutical composition of the present invention is a tablet.Non-oral formulation can be an injection, preparation capable of permeating skin, or spray etc., optimizing injection.Injection can be an infusion solutions, primary infusion, and little liquid drugs injection also can be a lyophilized injectable powder.
It should be understood by one skilled in the art that needs, in pharmaceutical composition of the present invention, often need to add again an amount of pharmaceutical carrier according to preparation.The kind of pharmaceutical carrier and consumption without limits, those of ordinary skills can freely select as required.For example pharmaceutical carrier can be starch (corn starch, potato starch etc.), Pulvis Talci, lactose, sucrose, calcium stearate, sodium stearate, glycerol, ethylene glycol or the like (can also give an example).Wherein be preferably starch.
In addition, in the pharmaceutical composition of the present invention, can also add an amount of additive as required.For example (can also give an example) such as correctives, spice, solubilizing agents.
Another object of the present invention provides the preparation method of aforementioned pharmaceutical compositions, and this method comprises 1) Radix Bupleuri is pulverized and is added 50%~80% ethanol lixiviate one or many of 3~6 times of amounts; Relative density is 1.15~1.25 when 2) extracting solution being evaporated to 50 ℃ of heat surveys, obtains Radix Bupleuri extractum; 3) with 2) gained extractum randomly mixes with the artificial Calculus Bovis, and drying is pulverized; 4) add baicalin and also randomly add an amount of pharmaceutical carrier, mix homogeneously, drying is granulated; 5) make required preparation as required.
In another concrete such scheme, the inventive method comprises 1) 50%~80% ethanol lixiviate of Radix Bupleuri being pulverized and adding 3~6 times of amounts; 2) filter twice of the lixiviate again of 3~6 times of amounts of medicinal residues reuse, 50%~80% ethanol; 3) merge extractive liquid,, relative density is 1.15~1.25 when being evaporated to 50 ℃ of heat surveys, is preferably 1.20~1.25, obtains Radix Bupleuri extractum; 4) with 3) gained extractum randomly mixes with the artificial Calculus Bovis, and drying is pulverized; 5) add Radix Scutellariae and also randomly add an amount of pharmaceutical carrier, mix homogeneously, drying is granulated; 6) make required preparation as required.
Preferably, used ethanol is 60% ethanol step 1) and 2 in the inventive method).More preferably, in the step 1) used ethanol be the 60% ethanol lixiviate of 5 times of amounts once, step 2) for measuring 60% ethanol lixiviate twice with 4 times.
Be appreciated that when the preparation Radix Bupleuri extractum, the ethanol water of the ethanol respective concentration that is added during lixiviate, its addition is in weight/volume, that is and, for 1 weight portion Radix Bupleuri medical material, the alcoholic solution that adds the respective volume multiple extracts.Particularly, if the weight of the Radix Bupleuri medical material that is extracted is 500 grams, then adds 4 times of amount 60% ethanol and be meant adding 2000mL60% ethanol water.
The baicalin that uses among the present invention can extract by known method with baikal skullcap root and prepare, and also can buy to obtain, and baicalin is a pale yellow powder, bitter in the mouth, purity be 85% or more than, preferred 90% or more than, more preferably wherein content of baicalin is 95%.Umbelliferae bupleurum (Bupleurum chinenseDC) also is a Chinese medicine, can use its herb, but preferably extracts Radix Bupleuri extract with its dry root.The artificial Calculus Bovis can buy from 25 tame enterprises such as bass Europe, Shanghai pharmaceutcal corporation, Ltds, is yellow loose powder, and bitter in the mouth is little sweet.
Radix Bupleuri adopts the ethanol extraction, and extracting with the saponin is Main Ingredients and Appearance alcohol soluble substance, has significantly reduced wherein compositions such as water solublity tannin, has improved curative effect, has reduced dose, makes things convenient for patient to take, and has improved stability of drug simultaneously, is beneficial to long term storage.
Most preferably, the invention provides a kind of capsulae anticoryzae (being also referred to as bilingual capsule), selected following composition of raw materials for use by baicalin, Radix Bupleuri and artificial Calculus Bovis's preparation:
Baicalin 45~135g, Radix Bupleuri 500~1500g, artificial Calculus Bovis 50~150g and starch 35~105g.
The consumption of above-mentioned each medicine components has been represented the proportionate relationship between them, can carry out expansion at double as required or dwindle in actual production, and this all belongs in protection scope of the present invention, can both show the pharmacological effect of its expection.Above-mentioned flavour of a drug be according to folk remedy in conjunction with clinical experience, the pharmacological experimental data of science in addition, comprehensive Design is formed, can bring into play pharmacological action separately, can play mutual synergism again, the pharmacology action effect is increased, can guarantee that again medicine does not change in storage.This product is through the clinical experiment result, and treatment virus causes influenza or go up the heating that sense causes, effective percentage such as pain reach 95%, is currently to cause influenza or go up the heating that sense causes, the better medicine of pain with Chinese medicine preparation treatment virus.This product is not only taken stopgap measures, and also effect a permanent cure, and effect is very fast.And as a comparison, the described oral liquid that the present inventor prepares by disclosed method among the CN1049600C is (because this oral liquid is ratified without Drug Administration, can not be used for clinical trial, therefore can't obtain clinical testing data), after placing for 1 week, room temperature just begins precipitation.Pharmaceutical composition of the present invention, significant change, steady quality do not take place in efficacy component in two years of storage.Every test item is all up to specification.
Pharmaceutical composition of the present invention is to be that raw material extracts the baicalin obtain with the natural plant Radix Scutellariae; Radix Bupleuri is that the raw material extraction obtains extractum and the artificial Calculus Bovis forms.This medicine has the function of heat-clearing and toxic substances removing.Be used for the treatment of influenza or go up the heating that sense causes, diseases such as pain.The reasonable compatibility of pharmaceutical composition of the present invention has reached special medical effect, and it is that each single composition institute is inaccessiable.
Product clinical testing data of the present invention and method
Test method:
1, randomized controlled clinical trial
2, select outpatient service and inpatient totally 200 examples, be divided into treatment group and matched group at random, each 100 example.
3, contrast medicinal GANMAO QINGRE JIAONANG, two cream packing.
4, three times on the oral one, one time 3, during taking this medicine, withdraw any medicine relevant with this disease.
5,3 days is a course of treatment, observes a course of treatment altogether.Before the treatment, body temperature, symptom variation are observed in the treatment back in the treatment.
6, completely learn method, group data is done X 2 test, measurement data is made the inspection level data and is done Ridit check.
Clinical testing data
1, each center test case situation
Each center case of table 1-1 distributes
Center 01 02 03 04 05 adds up to Go into to organize case load Case load comes off Reject case load Finish case load
The A group The B group The C group Add up to The A group The B group The C group Add up to The A group The B group The C group Add up to The A group The B group The C group Add up to
??24 ??24 ??24 ??24 ??24 ??120 ??24 ??24 ??24 ??24 ??24 ??120 ??24 ??24 ??24 ??24 ??24 ??120 ??72 ??72 ??72 ??72 ??72 ??360 ??0 ??3 ??0 ??0 ??0 ??3 ??1 ??5 ??0 ??0 ??2 ??8 ??1 ??4 ??0 ??0 ??2 ??7 ??2 ??12 ??0 ??0 ??4 ??18 ??1 ??0 ??0 ??0 ??0 ??1 ??2 ??0 ??0 ??0 ??0 ??2 ??0 ??0 ??0 ??0 ??0 ??0 ??3 ??0 ??0 ??0 ??0 ??3 ??23 ??21 ??24 ??24 ??24 ??116 ??21 ??19 ??24 ??24 ??22 ??110 ??23 ??20 ??24 ??24 ??22 ??113 ??67 ??60 ??72 ??72 ??68 ??339
Annotate: Huaxi Hospital Attached to Sichuan Univ 01, attached first hospital 02 of Hunan University of Traditional Chinese Medicine, attached second hospital 03 of Hunan University of Traditional Chinese Medicine, attached first hospital 04 of Guiyang College of Traditional Chinese Medicine, Hainan Province institute of traditional Chinese medicine 05.
Each center statistics case load of table 1-2
The center Meet the scheme collection The intentional analysis collection The safety collection
The A group The B group The C group Add up to The A group The B group The C group Add up to The A group The B group The C group Add up to
????01 ????02 ????03 ????04 ????05 ????23 ????21 ????24 ????24 ????24 ????21 ????49 ????24 ????24 ????22 ????23 ????20 ????24 ????24 ????22 ????67 ????60 ????72 ????72 ????68 ????23 ????22 ????24 ????24 ????24 ????22 ????21 ????24 ????24 ????22 ????23 ????20 ????24 ????24 ????22 ????68 ????63 ????72 ????72 ????68 ????24 ????24 ????24 ????24 ????24 ????24 ????24 ????24 ????24 ????24 ????24 ????24 ????24 ????24 ????24 ????72 ????72 ????72 ????72 ????72
Add up to ????116 ??110 ????113 ????339 ????117 ????113 ????113 ????343 ????120 ????120 ????120 ????360
2, MAIN OUTCOME MEASURES result and analysis
Table 3-1 comprehensive therapeutic effect is analyzed
Group ??n Recovery from illness Produce effects Effectively Invalid Total obvious effective rate Total effective rate
??n ??% ??n ????% ????n ????% ????n ??%
A group B group C group ??116 ??110 ??113 ??50 ??46 ??29 ??43.10 ??41.82 ??25.66 ??50 ??50 ??53 ??43.10 ??45.45 ??46.90 ????13 ????11 ????30 ????11.21 ????10.00 ????26.55 ????3 ????3 ????1 ??2.59 ??2.73 ??0.88 ?86.20 ?87.27 ?72.59 ?97.41 ?97.27 ?99.12
X 2=12.911??P=0.0016
Table 3-2 tcm symptom efficacy analysis
Group ??n Recovery from illness Produce effects Effectively Invalid Total obvious effective rate Total effective rate
??N ?% ??n ?% ????n ????% ????n ??%
The A group ??116 ????50 ?46.55 ??50 ?43.10 ????9 ????7.76 ????3 ???2.59 ?89.65 ?97.41
B group C group ?110 ?113 ?48 ?29 ?43.64 ?25.66 ?46 ?53 ?41.82 ?46.90 ????13 ????30 ????11.00 ????26.55 ????3 ????1 ??2.73 ??0.88 ??85.46 ??72.59 ??97.27 ??99.12
X 2=16.572??P=0.0003
Mean body temperature relatively before and after the table 3-3 treatment
Group ??n X ± S before the treatment Treatment back x ± S Difference x ± S ????F ????P
A group B group C group ?? ??116 ? ? ??110 ? ? ??113 ??37.85± ????0.41 ??37.88± ? ????0.38 ??37.95± ? ????0.43 ??36.82± ? ????0.42 ??36.84± ? ????0.35 ??36.89± ? ????0.48 ????1.031± ? ????????0.432 ????1.050± ? ????????0.424 ????1.028± ? ????????0.398 ? ? ? ?? ??0.09 ? ? ? ?? ??0.915
The cardinal symptom degree relatively before and after the table 3-4 treatment
Symptom heating slight chill pharyngalgia Group A group B group C group A group B group C group ?n ? ?? ?116 ?110 ?113 ?116 ?110 ?113 Before controlling In controlling After controlling
Do not have 000000 Light by 48 36 42 69 54 59 In 52 57 49 37 41 44 Weigh 16 17 22 10 15 10 Do not have 69 58 61 18 21 17 Light by 38 43 38 91 72 80 In 99 13 7 17 14 Weigh 001002 Do not have 108 101 93 81 73 59 Light by 55 18 34 37 49 In 341104 Weigh 001001
Heating slight chill: in the group: A group: Z1=8.547 P1=0.00; Z2=9.526 P2=0.00
B group: Z1=9.179 P1=0.00; Z2=9.288 P2=0.00
C group: Z1=9.559 P1=0.00; Z2=9.427 P2=0.00
Between group: Z1=1.324 P1=0.516
Z2=7.479??P2=0.024
In the pharyngalgia group: A group: Z1=7.761 P1=0.00; Z2=9.305 P2=0.00
B group: Z1=8.239 P1=0.00; Z2=9.289 P2=0.00
C group: Z1=7.464 P1=0.00; Z2=9.139 P2=0.00
Between group: Z1=1.520 P1=0.468
Z2=9.573?P2=0.0083
Body of the tongue relatively before and after the table 3-5 treatment
Group ????n Before controlling After controlling In the group Between group
Normally Red Normally Red ????P * ??X 2 ????P
A group B group C group ??116 ??110 ??113 ????4 ????4 ????4 ????112 ????106 ????109 ????82 ????76 ????66 ????34 ????34 ????47 ????0.00 ????0.00 ????0.00 ?4.512 ????0.105
Tongue fur relatively before and after the table 3-6 treatment
Group ????n Before controlling After controlling In the group Between group
Normally The book Huang Other Normally The book Huang Other ??P * ??X2 ??P
A group B group C group ?116 ?110 ?113 ?7 ?8 ?8 ?109 ?102 ?105 ?0 ?0 ?0 ?80 ?77 ?75 ?36 ?33 ?38 ?0 ?0 ?0 ?0.00 ?0.00 ?0.00 ? ??0.362 ? ??0.834
Pulse condition relatively before and after the table 3-7 treatment
Group ??n Before controlling After controlling In the group P between group *
Normally Floating number Normally Floating number ????X 2 ????P
A group B group C group ??116 ??110 ??113 ????34 ????36 ????32 ????82 ????74 ????81 ????111 ????105 ????95 ????5 ????5 ????18 ? ? ????71.34 ????0.00 ????0.00 ????0.00 ? ???0.003
Virus detects relatively before and after the table 3-8 treatment
Group ??n Before controlling After controlling In the group Between group
Negative (%) Positive (%) Negative (%) Positive (%) ?Z ??P ?X 2 ?P
A group B group C group ?93 ?89 ?94 65(69.89) 59(66.29) 64(68.82) 28(30.11) 30(23.71) 29(68.82) ??89(95.70) ??86(96.63) ??86(31.18) 4(4.30) 3(3.37) 8(7.53) ?4.899 ?5.196 ?4.690 ??0.00 ??0.00 ??0.00 ? ?1.807 ? ?0.405
The onset time distribution of table 3-9-1 body temperature is (h) relatively
Group ??n ???~12 ???~24 ???~48 ???~72 Not onset ??X 2 ????P
A group B group C group ??116 ??110 ??113 ????83 ????86 ????77 ????16 ????13 ????18 ????9 ????6 ????10 ????1 ????1 ????1 ????7 ????7 ????7 ? ??1.445 ? ??0.695
Table 3-9-2 mean body temperature onset time comparison (h)
Group ????n ?? x±S ????F ????P
A group B group C group ????109 ????105 ????107 ??10.29±11.80 ??9.67±8.80 ??11.73±13.32 ? ????0.90 ? ????0.41
The analgesic time of table 3-10-1 distributes compares (h)
Group ??n ??~12 ??~24 ??~48 ??~72 Not onset ??X 2 ???P
A group B group ??116 ??110 ??53 ??37 ??20 ??20 ??15 ??22 ??7 ??14 ????21 ????17 ??9.32 ???0.32
The C group ????113 ????44 ????19 ????16 ????8 ????26
The analgesic time ratio of table 3-10-2 mean body temperature is (h)
Group ????n ????? x±S ????F ????P
A group B group C group ????106 ????95 ????90 ????25.59±27.92 ????26.17±21.98 ????21.97±20.72 ? ????0.84 ? ????0.43
To sum up data shows, the present invention is feasible, effective, practical.
Embodiment
Provide the enforcement embodiments of the invention below, but be appreciated that these embodiment only are in order to further specify the present invention, and do not limit the present invention in any way.
Embodiment:
Embodiment 1
(1) prescription: baicalin: 135g, Radix Bupleuri: 1500g, artificial Calculus Bovis: 150g, starch: 80g.
(2) technology: Radix Bupleuri is ground into coarse powder, puts in the diafiltration tube, adds 5 times of amount 60% ethanol and stirs, and extracting solution is emitted in room temperature lixiviate two days.4 times of amounts of medicinal residues reuse, 60% ethanol extraction secondary; each two days, merge extractive liquid,, distilling under reduced pressure gets Radix Bupleuri extractum (relative density 1.20~1.25; 50 ℃ of heat are surveyed) mix with the artificial Calculus Bovis; drying under reduced pressure is ground into fine powder, adds baicalin fine powder and appropriate amount of starch; granulate; drying, encapsulated, obtain 1500 capsules.
Embodiment 2
(1) prescription: baicalin: 50g, Radix Bupleuri: 250g, starch: 15g.
(2) technology: the Radix Bupleuri decoction pieces is ground into coarse powder, puts in the diafiltration tube, adds 5 times of amount 65% ethanol and stirs, and extracting solution is emitted in room temperature lixiviate two days.4 times of amounts of medicinal residues reuse, 65% ethanol extraction secondary, each two days, merge extractive liquid,, distilling under reduced pressure gets Radix Bupleuri extractum (relative density 1.20~1.25,50 ℃ of heat are surveyed), drying under reduced pressure is ground into fine powder, adds baicalin fine powder and appropriate amount of starch, granulate, drying, tabletting obtains 600 bilingual.
Embodiment 3
(1): prescription: baicalin: 50g, Radix Bupleuri: 2500g, artificial Calculus Bovis: 250g, starch: 120g.
(2): technology: the Radix Bupleuri decoction pieces is ground into coarse powder, puts in the diafiltration tube, add 6 times of amount 75% ethanol and stir, extracting solution is emitted in room temperature lixiviate two days.4 times of amounts of medicinal residues reuse, 75% ethanol extraction secondary, each two days, merge extractive liquid,, distilling under reduced pressure gets Radix Bupleuri extractum (relative density 1.20~1.25; 50 ℃ of heat are surveyed) mix with the artificial Calculus Bovis, drying under reduced pressure is ground into fine powder, adds Radix Scutellariae fine powder and appropriate amount of starch; granulate, drying, encapsulated.
Embodiment 4
(1) prescription: baicalin: 90g, Radix Bupleuri: 1000g, water for injection: surplus.
(2) technology: the Radix Bupleuri decoction pieces is ground into coarse powder, puts in the diafiltration tube, add 5 times of amount 65% ethanol and stir, extracting solution is emitted in room temperature lixiviate two days.4 times of amounts of medicinal residues reuse, 65% ethanol extraction secondary, each two days, merge extractive liquid,, distilling under reduced pressure gets Radix Bupleuri extractum (relative density 1.20~1.25,50 ℃ of heat are surveyed), drying under reduced pressure is ground into fine powder, add in the 200mL distilled water for injection, stir and make the extractum dissolving, placement is spent the night, filter, other gets baicalin and is dissolved in the 200mL distilled water for injection, stirs, filter, two kinds of filtrates are merged, add distilled water for injection to 1000mL, sterilization, fill, promptly.

Claims (14)

1. pharmaceutical composition, it is characterized in that this pharmaceutical composition contain by weight 1~4 part of baicalin, by Radix Bupleuri extract, 0~5 part of artificial Calculus Bovis of 5~50 parts of Radix Bupleuri preparations.
2. according to the pharmaceutical composition of claim 1, it is characterized in that this pharmaceutical composition also contains an amount of pharmaceutical carrier.
3. according to the pharmaceutical composition of claim 2, wherein pharmaceutical carrier is a starch.
4. according to the pharmaceutical composition of claim 3, wherein said composition contains 1~2 part of baicalin by weight, by Radix Bupleuri extract and 1~2 part of artificial Calculus Bovis of 10~20 parts of Radix Bupleuri preparations.
5. according to the pharmaceutical composition of claim 4, wherein said composition contains 9 weight portion baicalins, by extract and 10 parts of weight artificial Calculus Boviss of 100 weight portion Radix Bupleuri preparation.
6. according to pharmaceutical composition any in the claim 1~5, wherein Radix Bupleuri extract prepares by following method: with 50%~80% ethanol lixiviate one or many, relative density was 1.15~1,25 when filtrate was concentrated into 50 ℃ of heat and surveys with Radix Bupleuri.
7. according to pharmaceutical composition any in the claim 1~6, wherein this pharmaceutical composition is solid orally ingestible, liquid oral medicine or injection.
8. according to the pharmaceutical composition of claim 7, wherein the Peroral solid dosage form solid preparation is capsule, tablet, granule or pill, dispersible tablet, effervescent tablet, chewable tablet or soft capsule.
9. according to the pharmaceutical composition of claim 7, wherein liquid oral medicine is mixture or oral liquid.
10. according to the pharmaceutical composition of claim 7, wherein injection is transfusion or little aqueous injection or lyophilized injectable powder.
11. prepare the method for the described pharmaceutical composition of claim 1, this method comprises 1) Radix Bupleuri pulverized and adds 50%~80% ethanol lixiviate one or many of 3~6 times of amounts; Relative density is 1.15~1.25 when 2) extracting solution being evaporated to 50 ℃ of heat surveys, obtains Radix Bupleuri extractum; 3) with 2) gained extractum randomly mixes with the artificial Calculus Bovis, and drying is pulverized; 4) add baicalin and also randomly add an amount of pharmaceutical carrier, mix homogeneously, drying is granulated; 5) make required preparation as required.
12. according to the method for claim 11, wherein used ethanol is 60% ethanol in the step 1).
13. according to the method for claim 11, wherein step 2) in to be concentrated into relative density be 1.20~1.25.
14. according to the method for claim 12, wherein step 1) is for measuring 60% ethanol lixiviate once, twice of 4 times of amounts of reuse, 60% ethanol lixiviate with 5 times.
CNB2005100678542A 2005-04-28 2005-04-28 Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method Active CN100512796C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2005100678542A CN100512796C (en) 2005-04-28 2005-04-28 Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2005100678542A CN100512796C (en) 2005-04-28 2005-04-28 Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method

Publications (2)

Publication Number Publication Date
CN1686423A true CN1686423A (en) 2005-10-26
CN100512796C CN100512796C (en) 2009-07-15

Family

ID=35304465

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100678542A Active CN100512796C (en) 2005-04-28 2005-04-28 Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method

Country Status (1)

Country Link
CN (1) CN100512796C (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100420456C (en) * 2006-03-14 2008-09-24 北京国丹药物技术开发有限公司 Compounded Radix Bupleuri enema preparation and preparing method
CN102641333A (en) * 2012-04-11 2012-08-22 河南灵佑药业有限公司 Sugar-free type Chaihuang granules and preparing method thereof
CN102106884B (en) * 2009-12-25 2013-08-21 财团法人工业技术研究院 Medicinal composition having immunity-regulating function
US8597693B2 (en) 2010-07-01 2013-12-03 Industrial Technology Research Institute Pharmaceutical composition with immunomodulating function
CN106309522A (en) * 2016-08-24 2017-01-11 扬子江药业集团上海海尼药业有限公司 Chaifei Qingning capsule and preparing method thereof

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100420456C (en) * 2006-03-14 2008-09-24 北京国丹药物技术开发有限公司 Compounded Radix Bupleuri enema preparation and preparing method
CN102106884B (en) * 2009-12-25 2013-08-21 财团法人工业技术研究院 Medicinal composition having immunity-regulating function
US8597693B2 (en) 2010-07-01 2013-12-03 Industrial Technology Research Institute Pharmaceutical composition with immunomodulating function
CN102641333A (en) * 2012-04-11 2012-08-22 河南灵佑药业有限公司 Sugar-free type Chaihuang granules and preparing method thereof
CN106309522A (en) * 2016-08-24 2017-01-11 扬子江药业集团上海海尼药业有限公司 Chaifei Qingning capsule and preparing method thereof
CN106309522B (en) * 2016-08-24 2017-07-28 扬子江药业集团上海海尼药业有限公司 Clear Yiganning capsule of bavin a kind of reed mentioned in ancient books and preparation method thereof

Also Published As

Publication number Publication date
CN100512796C (en) 2009-07-15

Similar Documents

Publication Publication Date Title
WO2009149585A1 (en) Compositions for reducing blood glucose level and uses thereof
CN1686423A (en) Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method
CN101732668B (en) Preparation method of Chinese medicinal composition for treating urinary system infection
CN101032547A (en) Anti-inflammatory and antivirotic medicine composition
CN1425447A (en) Traditional Chinese medicine composition for curing child's dyspepsia and cough and its preparing method
CN110623998B (en) Traditional Chinese medicine composition for diabetic peripheral neuropathy and application thereof
CN101002836B (en) Use of the extractive of radix cynanchi bungei total glucoside
CN1686424A (en) Medicinal composition containing scutellaria and bupleurum and its preparation method
CN102228547B (en) Application of traditional Chinese medicine composition in preparing medicaments treating pancreatitis and/or cholecystitis
CN1857697A (en) Compound Chinese medicine Anxuekang and its preparing method
CN101041037A (en) Drug for curing diabetes and nephropathy and its preparing method
CN1823982A (en) Chinese medicinal preparation for liver soothing and speen fortifying and its manufacturing method
CN1846775A (en) New medicinal use of Chinese medicine nutmeg and its extract
CN1421229A (en) Chinese medicine for treating hepatocirrhosis, hepatitis and liver cancer
CN103520684B (en) Traditional Chinese medicine compound for reducing blood sugar
CN105727089A (en) Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome
CN1237998C (en) Effervescence tablet for treating children's cough and asthma and its preparation
CN113058013A (en) Traditional Chinese medicine composition and preparation method and application thereof
CN1839956A (en) Pharmaceutical composition containing curcumin and its formulation
CN104352672A (en) Tortoise plastron-containing traditional Chinese medicine composition for treating diabetes
CN103316103A (en) Coccidian-expelling and dysentery-stopping mixture for livestock and preparation method thereof
CN1526441A (en) Agastache capsule for restoring healthy energy andits prepn and application
CN101322762B (en) Medicinal composition for treating diabetes
CN101391076A (en) Huidouba extract traditional Chinese medicine preparation for treating diabetes
CN100396295C (en) Medicine for treating virus hepatitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: HAINAN WANZHOU GREEN PHARMACY CO., LTD.

Free format text: FORMER OWNER: KUANG JIXIAN

Effective date: 20080523

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080523

Address after: Underwater sound code of Le Town, Hainan City, Wanning Province: 571500

Applicant after: Hainan Wanzhou Green Pharmaceutical Co., Ltd.

Address before: Hainan province Haikou City Jinlong Road No. 85 Lilongwe garden room C#-[3]-1301 post encoding: 570126

Applicant before: Kuang Jixian

ASS Succession or assignment of patent right

Owner name: HAINAN WANZHOU GREEN PHARMACY CO., LTD.; APPLICAN

Free format text: FORMER OWNER: HAINAN WANZHOU GREEN PHARMACY CO., LTD.

Effective date: 20080808

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080808

Address after: Underwater sound code of Le Town, Hainan City, Wanning Province: 571500

Applicant after: Hainan Wanzhou green Pharmaceutical Co., Ltd.

Co-applicant after: Liang Zetai

Address before: Underwater sound code of Le Town, Hainan City, Wanning Province: 571500

Applicant before: Hainan Wanzhou Green Pharmaceutical Co., Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Assignee: Haerbin Dongfang Pharmaceutical Co., Ltd.

Assignor: Liang Zetai

Contract fulfillment period: 2009.11.28 to 2011.11.27

Contract record no.: 2010990000026

Denomination of invention: Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method

Granted publication date: 20090715

License type: General permission

Record date: 2010.1.13

LIC Patent licence contract for exploitation submitted for record

Free format text: COMMON LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.11.28 TO 2011.11.27; CHANGE OF CONTRACT

Name of requester: HARBIN DONGFANG PHARMACY CO., LTD.

Effective date: 20100113

EE01 Entry into force of recordation of patent licensing contract

Assignee: Yangtze River Pharmaceutical Co., Ltd.

Assignor: Liang Zetai

Contract record no.: 2012990000168

Denomination of invention: Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method

Granted publication date: 20090715

License type: Common License

Open date: 20051026

Record date: 20120331

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20181214

Address after: 225300 No. 9, Longfeng Tang Road, Yongan Town, Taizhou, Jiangsu.

Co-patentee after: Yangtze River Pharmaceutical Co., Ltd.

Patentee after: Yangzi Pharmaceutical Group Jiangsu Longfeng traditional Chinese Medicine Co., Ltd.

Address before: 571500 Water Sound of Lelai Town, Wanning City, Hainan Province

Co-patentee before: Liang Zetai

Patentee before: Hainan Wanzhou Green Pharmaceutical Co., Ltd.